Biocon Biologics India Limited

Biocon Biologics India Limited is India’s largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. Biocon’s key innovations include an indigenous recombinant human insulin based on proprietary fermentation technology, Insugen®; insulin analog Glargine, Basalog®; India’s first indigenously produced monoclonal antibody, BIOMAb-EGFR®; the world’s first humanized anti-CD6 monoclonal antibody, Itolizumab, launched as ALZUMAb™ in India; CANMAb™, the first follow-on biologic Trastuzumab to be approved anywhere in the world.


CELON LABORATORIES (PVT) LTD., INDIA is a specialty-focused pharmaceutical company with core competencies in Oncology and Critical Care.  Celon Labs is a leader in the development and marketing of specialty products which serve niche therapy areas. Using in-house research & development capabilities, operational flexibility, manufacturing and regulatory expertise, Celon has taken a wide variety of products from laboratory to the market. They are committed to create better quality of life by being at the forefront of research, manufacturing and marketing of high quality formulations. Celon manufactures and markets a comprehensive portfolio of Oncology products and a vital portfolio of critical care products with a commitment to deliver wellness across the globe. Celon’s branded formulations business has domestic & international reach with focus on Indian & ROW markets. Their future endeavor in Global generics is all set to foray into the regulated markets.

Daewoong Pharmaceutical Co., Ltd.

Daewoong Pharmaceutical Co., Ltd. Korea, established in 1945 has the largest prescription drug sales in Korea and envisions itself to become a top 50 global healthcare company by 2020.  In addition to its product portfolio, which includes 15 blockbuster products, Daewoong has built strong core competency for new drug development and has cultivated a cooperative culture for collaboration with global partners. They envisage to expand global business with their foreign branches and global partners and become a global healthcare group which contributes to improving the quality of life for people worldwide.  Daewoong has applied its business expertise and knowledge in Korea to penetrate the vast Asian market and strives to be the best pharmaceutical business partner for global pharmaceutical companies entering the Asian market.

GKM New Pharma

GKM New Pharma brings forth highly effective and safe medicines. With constant efforts, they have become one of the leading manufacturers and exporters of the same. It’s having wide range of products in tablets, Capsules, Liquid and oral suspension. GKM range of products includes Balofloxacin, Lafutidine, Rosuvastatin, Clopidogrel, Zinc Carnosine, Glibenclamide, Glimepiride, Estizolam Escitaloparm Oxalate Tablets & Aspirin Capsules and many more. The company have a team of experienced medicos, quality assurance, quality control, researchers, packaging experts, supervisors and marketing executives. GKM quality assurance & quality control system ensure that all products conform to established medical norms and standards. Beside this, GKM company also has separate research & development team, who research new drugs and discover their suitability for human body as medications.


Biomecanica is evolving and always seek the best for the patients, for this they have invest in new knowledge, such as nanotechnology and biomaterials. They created the Orion SP Series in conjunction with companies, government and universities in Switzerland, company guarantee quality and innovation thus provide internationalization of the products, making them recognized worldwide. More than square meters in a factory with machinery and equipment, are people committed to health, this is the mission. The products online go beyond physical rehabilitation; they carry within themselves the essence of life. They are recognized because they believe in the orthopedic market and design the products with the thought always the end user.


CIMAB SA is a Cuban biopharmaceutical institute. “Excellence and Confidence …” Since 1992 CIMAB SA is dedicated to the marketing of biopharmaceuticals in the domestic and international markets, especially monoclonal antibodies and other recombinant proteins for the diagnosis and treatment of cancer and other diseases related to the immune system. CIMAB SA is the exclusive representative of the Center of Molecular Immunology (CIM), also represents the “Laboratories AICA” and Plant cytostatic CIDEM for the commercialization of some of its pharmaceutical products. CIMAB SA’s main mission is export of new biological medicines for the treatment of cancer and other chronic and non-transmitted diseases.